Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Barousse

Orthopaedic Surgery Reno, NV Medical Doctor

NPI 1053759555 CMS profile 1278437

555 N Arlington Ave, Reno, NV 89503

Open in the dashboard

General payments

$14,449

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Barousse of Reno, NV is reported in the CMS Open Payments database as having received $14,449 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,470 27
2024 General $160 5
2023 General $538 11
2022 General $3,724 25
2021 General $1,891 11
2020 General $521 10
2019 General $4,145 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Barousse
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Patrick Barousse were reported at $3,470. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Patrick Barousse Orthopaedic Surgery median Middle half National median
2019 $4,145 $644 $140–$2,844 $163
2020 $521 $312 $75–$1,860 $114
2021 $1,891 $520 $117–$2,495 $132
2022 $3,724 $598 $128–$2,731 $149
2023 $538 $461 $128–$2,264 $160
2024 $160 $497 $134–$2,475 $164
2025 $3,470 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,769 74 payments
  2. Alon Medical Technology $4,582 17 payments
  3. Arthrex, Inc. $3,671 28 payments
  4. DePuy Synthes Sales Inc. $657 8 payments
  5. Crossroads Extremity Systems, LLC $342 3 payments
  6. Wright Medical Technology, Inc. $114 3 payments
  7. Sequoia Surgical, Inc. $105 1 payment
  8. Smith+Nephew, Inc. $68 2 payments
  9. Globus Medical, Inc. $35 1 payment
  10. Zimmer Biomet Holdings, Inc. $29 1 payment
  11. Other $80 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,206 117 payments
  2. Travel and Lodging $4,328 20 payments
  3. Education $3,600 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,250 1 payment
  5. Gift $65 1 payment
Products named General payments · program years 2019–2025
  1. HOFFMANN Trauma & Extremeties $1,636 13 payments
  2. STAR Trauma & Extremeties $988 9 payments
  3. SONICANCHOR $786 2 payments
  4. PROSTEP $543 2 payments
  5. ACCULIF $346 4 payments
  6. AUGMENT INJECTABLE $335 5 payments
  7. HOFFMANN Trauma & Extremeties $271 4 payments
  8. DISTAL EXTREMITIES IMPLANTS FRACTURE MANAGEMENT ANKLE FRACTURE $186 2 payments
  9. NA $164 3 payments
  10. STAR Trauma & Extremeties $151 1 payment
  11. Other $2,823 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

49

Median for Orthopedic Surgery: 203

Drug cost

$221

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 20 $80
Hydroxyzine Pamoate Generic 18 $74
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$34,850

Medicare's payments for the services billed

Medicare patients

146

Average age 72

Services billed

301

88 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 41%
Depression 33%
Diabetes 29%
COPD 29%
Heart failure 27%
Chronic kidney disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record